UPDATE: Piper Jaffray Raises PT on BioMarin Pharmaceutical on Positive Trial Results
In a report published Wednesday, Piper Jaffray analyst M Ian Somaiya reiterated an Overweight rating on BioMarin Pharmaceutical (NASDAQ: BMRN), and raised the price target from $64.00 to $70.00.
In the report, Somaiya noted, “BioMarin announced positive results from POM-001, the Phase I/II trial of BMN-701 in Pompe disease and confirmed its intention to advance ‘701 into Phase II/III by YE13. Overall, we believe the data are positive, with patients achieving meaningful improvements in pulmonary function and greater proportion of super responders in 6MWD. However, we believe the bar for success was relatively low, given go/no-go criteria outlined on the 4Q call and Myozyme's modest efficacy. Additionally, we note some variability in the data including lack of change in select pulmonary function measures (FVC).”
BioMarin Pharmaceutical closed on Tuesday at $60.76.
Latest Ratings for BMRN
|Apr 2016||BMO Capital||Initiates Coverage on||Outperform|
|Mar 2016||Credit Suisse||Maintains||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.